Identification and characterization of a novel fermented substance produced by edible Aspergillus oryzae AO-1 that inhibits DPP-IV activity

Journal of Bioscience and Bioengineering

Volumn 111, Issue 1, 2011, Pages 37-40

  Imamura, Kazuhiko ^a   Tsuyama, Yoshihito ^a   Hirata, Terukage ^a  

^a WAKUNAGA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Antihyperglycemia; Aspergillus oryzae; Diabetes; Dipeptidyl peptidase IV; Fermentation products

Indexed keywords

ANTIHYPERGLYCEMIA; ASPERGILLUS ORYZAE; DIABETES; DIPEPTIDYL PEPTIDASE; FERMENTATION PRODUCTS;

FERMENTATION;

STRAIN;

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; TETRAHYDROXYISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; WYK 1;

ARTICLE; ASPERGILLUS ORYZAE; CONTROLLED STUDY; DRUG IDENTIFICATION; EDIBLE MUSHROOM; ENZYME ACTIVITY; ENZYME INHIBITION; FUNCTIONAL FOOD; FUNGAL STRAIN; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLITE; NONHUMAN;

ASPERGILLUS ORYZAE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FERMENTATION; PHYLOGENY; TETRAHYDROISOQUINOLINES;

ASPERGILLUS ORYZAE;

EID: 78650981558     PISSN: 13891723     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiosc.2010.08.013     Document Type: Article

References (19)

1. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul. Pept. 1999, 85:9-24.
2. Verspohl E.J. Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagons-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol. Ther. 2009, 124:113-138.
3. Holst J., Deacon C. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 1998, 47:1663-1670.
4. Pederson A.R., White A.H., Schlenzig D., Pauly P.R., Mclntosh H.S.C., Demuth H.U. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 1998, 47:1253-1257.
5. Balkan B., Kwasnik L., Miserendino R., Holst J.J., Li X. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 1999, 42:1324-1331.
6. Ahren B., Holst J.J., Martensson H., Balkan B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur. J. Pharmacol. 2000, 404:239-245.
7. Reimer N.K., Holst J.J., Ahren B. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur. J. Endocrinol. 2002, 146:717-727.
8. Ahren B., Simonsson E., Larsson H., Landin-Olsson Mona., Torgeirsson H., Jansson P.A., Sandqvist M., Bavenholm P., Efendic S., Eriksson J.W., Dickinson S., Holmes D. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002, 25:869-875.
9. Ahren B., Landin-Olsson M., Jansson P.A., Svensson M., Holmes D., Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J. Clin. Endocrinol. Metab. 2004, 89:2078-2084.
10. Covington P., Christopher R., Davenport M., Fleck P., Mekki Q.A., Wann E.R., Karim A. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin. Ther. 2008, 30:499-512.
11. Utzschneider K.M., Tong J., Montgomery B., Udayasankar J., Gerchman F., Marcovina S.M., Watson C.E., Ligueros-Saylan M.A., Foley J.E., Holst J.J., Deacon C.F., Kahn S.E. the dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care 2008, 31:108-113.
12. Williams-Herman D., Round E., Swern A.S., Musser B., Davies M.J., Stein P.P., Kaufman K.D., Amatruda J.M. Safty and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrinol. Disord. 2008, 8:14.
13. Machida M., Asai K., Sano M., Tanaka T., Kumagai T., Terai G., Kusumoto K., Arima T., Akita O., Kashiwagi Y., other 54 authors Genome sequencing and analysis of Aspergillus oryzae. Nature 2005, 438:1157-1161.
14. Lee B.R., Yamada O., Kitamoto K., Takahashi K. Cloning, characterization and overexpression of a gene (pdiA) encoding protein disulfide isomerase of Aspergillus oryzae. J. Ferment. Bioeng. 1996, 82:538-543.
15. Kusumoto K., Nogata Y., Ohta H. Directed deletions in the aflatoxin biosynthesis gene homolog cluster of Aspergillus oryzae. Curr. Genet. 2000, 37:104-111.
16. Tominaga M., Lee Y.H., Hayashi R., Suzuki Y., Yamada O., Sakamoto K., Gotoh K., Akita O. Molecular analysis of an inactive aflatoxin biosynthesis gene cluster in Aspergillus oryzae RIB strains. Appl. Environ. Microbiol. 2006, 72:484-490.
17. Asai Y., Nonaka N., Nishio M., Okamura K., Date T., Sugita T., Ohnuki T. TMC-2A, -2B and -2C, new dipeptidyl peptidase IV inhibitors produced by Aspergillus oryzae A374 II. Isolation and structure determination. J. Antibiot. 1998, 50:653-658.
18. Nonaka N., Asai Y., Nishio M., Takahashi K., Okuda T., Tanaka S., Sugita T. TMC-2A, -2B and -2C, novel dipeptidyl peptidase IV inhibitors produced by Aspergillus oryzae A374. I. Taxonomy of producing strain, fermentation, and biochemical properties. J. Antibiot. 1997, 50:646-652.
19. Doumas A., Broek P., Affolter M., Monod M. Characterization of the prolyl dipeptidyl peptidase gene (dppIV) from the Koji Mold Aspergillus oryzae. Appl. Environ. Microbiol. 1998, 64:4809-4815.